Background More women than men have heart failure with preserved ejection fraction
(HFpEF). Objectives The purpose of this study was to assess baseline characteristics and …

Background Many therapies for heart failure (HF) have shown differential impact across the
spectrum of left ventricular ejection fraction (LVEF). Objectives In this prespecified analysis …

Abstract Background In the Semaglutide Treatment Effect in People with obesity and HFpEF
(STEP-HFpEF) program, semaglutide improved heart failure (HF)-related symptoms …

Abstract Background and Aims In the STEP-HFpEF trial program, treatment with semaglutide
resulted in multiple beneficial effects in patients with obesity-related heart failure with …

Background Heart failure with preserved ejection fraction is increasing in prevalence and is
associated with a high symptom burden and functional impairment, especially in persons …

Background Obesity is associated with adverse cardiac remodeling and is a key driver for
the development and progression of heart failure (HF). Once-weekly semaglutide (2.4 mg) …

Summary Background In the STEP-HFpEF (NCT04788511) and STEP-HFpEF DM
(NCT04916470) trials, the GLP-1 receptor agonist semaglutide improved symptoms …

BACKGROUND: Patients with heart failure (HF) with preserved ejection fraction (HFpEF)
and obesity experience a high burden of symptoms and functional impairment, and a poor …

Background Semaglutide, a once‐weekly glucagon‐like peptide‐1 receptor agonist, has
shown promise in weight management and cardiovascular outcomes in other populations …

Background Obesity and type 2 diabetes are prevalent in patients with heart failure with
preserved ejection fraction and are characterized by a high symptom burden. No approved …